Filing Flows › RxSight (RXST) › Q3 2026
RxSight (RXST) Q3 2026 earnings results (third quarter 2026)
10-Q filed Nov 3, 2026
RxSight (RXST) reported revenue of $24.6M for the third quarter 2026 (Q3 2026), -19% from a year earlier and -27% from the quarter before. Operating margin was -75.3%, net loss $16.2M (66.0% of revenue).
RxSight, Q3 2026: revenue $24.6M (-19% year over year), operating margin -75.3%, net loss $16.2M, operating cash flow $45.2M. The chart follows the revenue to costs, profit and cash.
| Q3 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $24.6M | -27% | -19% |
| Operating profit | −$18.5M | — | — |
| Net earnings | −$16.2M | — | — |
| Operating cash flow | $45.2M | — | — |
| Free cash flow | $44.0M | — | — |
What changed
Revenue was $24.6M in Q3 2026, down 19% year over year and down 27% from the previous quarter. Rxlal was the largest line at 93% of revenue. Rxlal lost $2.9M year over year (down 11%), 51% of the total change.
Operating costs exceeded revenue by $18.5M, an operating margin of -75.3%. The quarter ended with a net loss of $16.2M, wider than the previous quarter's $12.1M loss.
Operating cash flow was $45.2M. Non-cash charges added back $929K of depreciation and amortization and $7.6M of share-based compensation. Working capital and other items added $52.9M. Capital expenditures of $1.2M left free cash flow of $44.0M.
Questions
What was RxSight's revenue in the third quarter 2026?
RxSight (RXST) reported revenue of $24.6M for the third quarter 2026 (Q3 2026), -19% from a year earlier and -27% from the quarter before.
Was RxSight profitable in the third quarter 2026?
Operating loss was $18.5M (-75.3% of revenue) and net loss $16.2M.
Source: RxSight 10-Q on SEC EDGAR.